Clockwise from top left, Alice Y.Y. Cheng, MD, FRCPC, Francesco Giorgino, MD, PhD, Daniel J. Drucker, MD, Michelle Welch, MD, FACE, Carol H. Wysham, MD, and Juan Pablo Frias, MD, discuss questions from Scientific Sessions attendees following a Tuesday morning symposium on SURPASS trial results. View this session and the Q&A discussion on-demand.
Q&A: Next Chapter in Incretin-Based Therapies—Tirzepatide, a Novel Dual GIP/GLP-1 Receptor Agonist—Results from the First Phase 3 SURPASS Clinical Trials
